ALNY Alnylam Pharmaceuticals Inc

USD 269.95 -3.96 ( -1.45)%
Icon

Alnylam Pharmaceuticals Inc (ALNY) Stock Analysis and Price Targets

COMMON STOCK | Biotechnology | NSD
stockTargetAdvisor

Strong Buy

Average Analyst
Rating
stockTargetAdvisor

Strong Buy

Top Analyst
Rating
stockTargetAdvisor

Bullish

Stock Target Advisor
Analysis
stockTargetAdvisor

Buy

Average User
Rating

USD 269.95

-3.96 (-1.45)%

USD 35.33B

0.78M

USD 285.92(+5.92%)

USD 198.25 (-26.56%)

Icon

ALNY

Alnylam Pharmaceuticals Inc (USD)
COMMON STOCK | NSD
USD 269.95
-3.96 ( -1.45)%
stockTargetAdvisor

Strong Buy

Average Analyst
Rating
stockTargetAdvisor

Strong Buy

Top Analyst
Rating
stockTargetAdvisor

Bullish

Stock Target Advisor
Analysis
stockTargetAdvisor

Buy

Average User
Rating

USD 35.33B

USD 198.25 (-26.56%)

USD 269.95

Alnylam Pharmaceuticals Inc (ALNY) Stock Forecast

Show ratings and price targets of :
USD 285.92
(+5.92%)

Based on the Alnylam Pharmaceuticals Inc stock forecast from 21 analysts, the average analyst target price for Alnylam Pharmaceuticals Inc is USD 285.92 over the next 12 months. Alnylam Pharmaceuticals Inc’s average analyst rating is Strong Buy. Stock Target Advisor’s own stock analysis of Alnylam Pharmaceuticals Inc is Bullish , which is based on 8 positive signals and 3 negative signals. At the last closing, Alnylam Pharmaceuticals Inc’s stock price was USD 269.95. Alnylam Pharmaceuticals Inc’s stock price has changed by -5.91% over the past week, +0.73% over the past month and +61.31% over the last year.

No recent analyst target price found for Alnylam Pharmaceuticals Inc
No recent average analyst rating found for Alnylam Pharmaceuticals Inc

Company Overview Alnylam Pharmaceuticals Inc

Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing, and commercializing novel therapeutics based on ribonucleic acid interference. Its marketed products include ONPATTRO (patisiran) for the treatment of the polyneuropathy of hereditary ...Read More

https://www.alnylam.com

675 West Kendall Street, Cambridge, MA, United States, 02142

2,100

December

USD

USA

Adjusted Closing Price for Alnylam Pharmaceuticals Inc (ALNY)

Loading...

Unadjusted Closing Price for Alnylam Pharmaceuticals Inc (ALNY)

Loading...

Share Trading Volume for Alnylam Pharmaceuticals Inc Shares

Loading...

Compare Performance of Alnylam Pharmaceuticals Inc Shares

Symbol Capital Gain Dividend Return Total Return
Loading...
Loading...

Technical Indicators for ALNY

Assets

Top Holdings

Top Sectors

Top Regions

Stocks Similar To Alnylam Pharmaceuticals Inc (Sector: Biotechnology )

Symbol Name Price(Change) Market Cap Price / Earning Ratio EV/EBITDA
VRTX
Vertex Pharmaceuticals Inc +1.68 (+0.36%) USD121.60B 32.57 250.99

Frequently Asked Questions About Alnylam Pharmaceuticals Inc (ALNY) Stock

Based on ratings from 21 analysts Alnylam Pharmaceuticals Inc's stock is Strong Buy. Stock Target Advisor's fundamental analysis is Bullish . The stock has 35 buy, sell and 11 hold ratings.

Unfortunately we do not have enough data on ALNY's stock to indicate if its a good dividend stock.

Based on targets from 21 analysts, the average taret price for ALNY is USD 285.92 over the next 12 months. The maximum analyst target price is USD 400 while the minimum anlayst target price is USD 125.

Unfortunately we do not have enough data on ALNY's stock to indicate if its overvalued.

The last closing price of ALNY's stock was USD 269.95.

The most recent market capitalization for ALNY is USD 35.33B.

Based on targets from 21 analysts, the average taret price for ALNY is projected at USD 285.92 over the next 12 months. This means that ALNY's stock price may go up by +5.92% over the next 12 months.

We can't find any ETFs which contains Alnylam Pharmaceuticals Inc's stock.

As per our most recent records Alnylam Pharmaceuticals Inc has 2,100 Employees.

Alnylam Pharmaceuticals Inc's registered address is 675 West Kendall Street, Cambridge, MA, United States, 02142. You can get more information about it from Alnylam Pharmaceuticals Inc's website at https://www.alnylam.com.
Heading 1 Heading 2 Heading 3 Heading 4 Heading 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5

Stock Target Advisor's Analysis

This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.

Icon
What to like

Icon
What not to like

Frequently Asked Questions About Alnylam Pharmaceuticals Inc (ALNY) Stock

Based on ratings from 21 analysts Alnylam Pharmaceuticals Inc's stock is Strong Buy. Stock Target Advisor's fundamental analysis is Bullish . The stock has 35 buy, sell and 11 hold ratings.

Unfortunately we do not have enough data on ALNY's stock to indicate if its a good dividend stock.

Based on targets from 21 analysts, the average taret price for ALNY is USD 285.92 over the next 12 months. The maximum analyst target price is USD 400 while the minimum anlayst target price is USD 125.

Unfortunately we do not have enough data on ALNY's stock to indicate if its overvalued.

The last closing price of ALNY's stock was USD 269.95.

The most recent market capitalization for ALNY is USD 35.33B.

Based on targets from 21 analysts, the average taret price for ALNY is projected at USD 285.92 over the next 12 months. This means that ALNY's stock price may go up by +5.92% over the next 12 months.

We can't find any ETFs which contains Alnylam Pharmaceuticals Inc's stock.

As per our most recent records Alnylam Pharmaceuticals Inc has 2,100 Employees.

Alnylam Pharmaceuticals Inc's registered address is 675 West Kendall Street, Cambridge, MA, United States, 02142. You can get more information about it from Alnylam Pharmaceuticals Inc's website at https://www.alnylam.com.
Loading...